Biomarin Pharmaceutical News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.09.17	BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017 (PR Newswire)
05.09.17	BioMarin Announces 3 Platform and 15 Poster Presentations at 13th International Congress of Inborn Errors of Metabolism 2017 (PR Newswire)
30.08.17	APRI Makes 2nd Try, PRQR To Reveal Data On Sep.25, PFE Awaits FDA Decision (RTTNews)
30.08.17	FDA Accepts BioMarin's Pegvaliase BLA And Grants Priority Review Designation (RTTNews)
29.08.17	FDA Accepts BioMarin's Pegvaliase Biologics License Application (BLA) and Grants Priority Review Designation (PR Newswire)
25.08.17	Technical Snapshots for these Biotech Stocks -- Gilead Sciences, Biogen, bluebird bio, and BioMarin Pharma (PR Newswire)
23.08.17	BioMarin Announces Exercise in Full of Underwriters' Option to Purchase Additional 0.599% Senior Subordinated Convertible Notes Due 2024 (PR Newswire)
21.08.17	Forbes Ranks BioMarin 12th Most Innovative Company in the World (PR Newswire)
15.08.17	BioMarin to Attend Upcoming Investor Conferences (PR Newswire)
08.08.17	BioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024 (PR Newswire)
02.08.17	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q2 Earnings Report (RTTNews)
02.08.17	BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies (PR Newswire)
31.07.17	BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET (PR Newswire)
18.07.17	BioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET (PR Newswire)
11.07.17	BioMarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels within Normal Range for over One Year (PR Newswire)
23.06.17	Technical Research on Biotech Equities -- Celsion, Sarepta Therapeutics, BioMarin Pharma, and ContraVir Pharma (PR Newswire)
16.06.17	BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis 2017 Congress (PR Newswire)
12.06.17	FDA Approves BioMarin's Manufacturing Facility Located in Shanbally, Cork, Ireland (PR Newswire)
01.06.17	BioMarin Reports Marketing Authorization For Brineura In European Union (RTTNews)
01.06.17	European Commission Approves Brineura™ (cerliponase alfa), the First Treatment for CLN2 Disease, a Form of Batten Disease and Ultra-Rare Brain Disorder in Children (PR Newswire)
31.05.17	BioMarin to Attend Upcoming Investor Conference (PR Newswire)
09.05.17	Biotech Stocks on Investors' Radar -- BioMarin Pharma, Eyegate Pharma, Navidea Biopharma, and Cellectar Biosciences (PR Newswire)
04.05.17	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q1 Earnings Report (RTTNews)
04.05.17	BioMarin Announces First Quarter 2017 Financial Results (PR Newswire)
02.05.17	BioMarin to Attend Two Upcoming Investor Conferences (PR Newswire)
28.04.17	FDA Oks BioMarin's Brineura As Treatment For Specific Form Of Batten Disease (RTTNews)
27.04.17	FDA Approves Brineura™ (cerliponase alfa) for the Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare Pediatric Brain Disorder in Children (PR Newswire)
21.04.17	BioMarin Receives Positive CHMP Opinion in Europe for Brineura™ (cerliponase alfa) for First Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare and Fatal Brain Disorder in Children (PR Newswire)
20.04.17	BioMarin to Host First Quarter 2017 Financial Results Conference Call and Webcast on Thursday, May 4 at 4:30pm ET (PR Newswire)
13.04.17	BioMarin Enters Into Settlement Agreement With Par Pharma Related To Kuvan (RTTNews)
13.04.17	BioMarin Announces Kuvan® (sapropterin dihydrochloride) Patent Challenge Settlement (PR Newswire)
24.03.17	Biotech Stocks Facing FDA Decision In April (RTTNews)
13.03.17	Technical Reports on Biotech Stocks -- Nektar Therapeutics, Seattle Genetics, Dynavax Technologies, and BioMarin Pharma (PR Newswire)
23.02.17	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q4 Earnings Report (RTTNews)
23.02.17	BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results (PR Newswire)
15.02.17	BioMarin Announces 11 Presentations at 13th Annual WORLDSymposium™ 2017 (PR Newswire)
08.02.17	BioMarin to Attend Three Investor Conferences in 1Q17 (PR Newswire)
07.02.17	BioMarin to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on Thursday, February 23 at 4:30pm ET (PR Newswire)
01.02.17	BioMarin Receives Access to Priority Medicines (PRIME) Regulatory Support from EMA for BMN 270 Gene Therapy in Hemophilia A (PR Newswire)
09.01.17	Research Reports Initiation on Biotech Stocks -- ImmunoGen, BioMarin Pharma, CEL-SCI, and Dipexium Pharma (PR Newswire)
30.11.16	Research Reports Coverage on Biotech Stocks -- Biogen, BioMarin Pharma, Seattle Genetics, and Grifols (PR Newswire)
27.10.16	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q3 Earnings Report (RTTNews)
22.09.16	BMRN To Seek Review Of PTAB Ruling, CERC Awaits Phase 2 Data In Nov, OCRX Abuzz (RTTNews)
16.09.16	ARLZ Gets FDA Nod, ACRX Scores Hat Trick, OTIC On Watch, No Relief For NVAX (RTTNews)
15.09.16	BioMarin Reports EMA Validation Of Brineura MAA For Treatment Of CLN2 Disease (RTTNews)
07.09.16	CERC Data Due Dec., SAMURAI Brings Cheer To CLCD, TNXP Slumps As Study Fails (RTTNews)
07.09.16	BioMarin Updates On Brineura Program For Treatment Of CLN2 Disease (RTTNews)
04.08.16	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q2 Earnings Report (RTTNews)
07.07.16	BioMarin Pulls Back Off Best Levels But Holding On To Strong Gain (RTTNews)
01.06.16	BMRN Pulls The Plug On DMD Drug, LXRX To Face FDA In Nov, TEVA Snubbed (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

16.09.24		NASDAQ Composite aktuell: NASDAQ Composite schlussendlich im Minus
16.09.24		NASDAQ-Handel So entwickelt sich der NASDAQ Composite am Nachmittag
16.09.24		Anleger in New York halten sich zurück: NASDAQ Composite am Montagmittag schwächer
16.09.24		Verluste in New York: NASDAQ Composite verliert zum Start
06.08.24		Freundlicher Handel in New York: NASDAQ Composite zum Handelsende im Plus
06.08.24		Freundlicher Handel: NASDAQ Composite am Nachmittag freundlich
06.08.24		Handel in New York: NASDAQ Composite mittags mit grünem Vorzeichen
06.08.24		Börse New York in Grün: NASDAQ Composite zum Start des Dienstagshandels in Grün

16.09.24

NASDAQ Composite aktuell: NASDAQ Composite schlussendlich im Minus

16.09.24

NASDAQ-Handel So entwickelt sich der NASDAQ Composite am Nachmittag

16.09.24

Anleger in New York halten sich zurück: NASDAQ Composite am Montagmittag schwächer

16.09.24

Verluste in New York: NASDAQ Composite verliert zum Start

06.08.24

Freundlicher Handel in New York: NASDAQ Composite zum Handelsende im Plus

06.08.24

Freundlicher Handel: NASDAQ Composite am Nachmittag freundlich